The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient knowledge, attitudes, and expectations of cancer immunotherapies.
 
Simranjot Shokar
No Relationships to Disclose
 
Elena Buldo
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; MorphoSys; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Merck Serono; Pfizer
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Merck; Novartis
 
Jeffrey Doi
No Relationships to Disclose
 
Lindsay Carlsson
No Relationships to Disclose
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)